Latest data from the Hong Kong Stock Exchange shows that on November 3, Chairman Li Qiling purchased an additional 52,000 shares of DAWNRAYS PHARMA (02348) at HK$1.22 per share, totaling approximately HK$63,400. Following this transaction, Li's total holdings reached approximately 711 million shares, representing a 47.26% stake. The transaction also involved another related party: Xiong Rongli.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.